多巴胺D2受体拮抗剂可正常化NASH中促纤维化巨噬细胞-内皮细胞交互
该研究在小鼠肝纤维化模型、小型猪NASH模型及人肝硬化肝活检中,发现巨噬细胞YAP水平升高并促进纤维化;通过GPCR配体筛选系统鉴定出多巴胺D2受体(DRD2)拮抗剂可选择性阻断巨噬细胞YAP,从而减轻肝纤维化并在大型动物模型中恢复肝脏结构。
要点
- 巨噬细胞YAP在肝纤维化中升高并促进纤维化。
- DRD2拮抗剂选择性阻断巨噬细胞YAP而非肝细胞YAP。
- DRD2拮抗在啮齿类和小型猪NASH模型中减轻纤维化。
核心结论
- DRD2拮抗选择性靶向巨噬细胞与CTGF+VCAM1+血管龛之间的YAP依赖性促纤维化交互,在 rodent 和大型动物模型中促进肝再生而非纤维化。
研究设计与样本
- 使用小鼠肝纤维化模型、小型猪NASH模型及人肝硬化肝活检,并进行单细胞RNA测序和GPCR配体筛选系统。
主要发现
- 在人类和小鼠纤维化肝脏中巨噬细胞YAP水平升高。
- 髓系细胞特异性缺失Yap1的小鼠中I型干扰素增加且肝纤维化减轻。
- 单细胞RNA测序显示巨噬细胞YAP通路信号缺陷减少具有促纤维化分子特征(如血管分泌CTGF和VCAM1表达)的促纤维化血管内皮细胞亚群。
- GPCR配体筛选系统鉴定出DRD2拮抗剂选择性阻断巨噬细胞而非肝细胞的YAP。
- 遗传和药理学靶向巨噬细胞DRD2减轻肝纤维化,且在小型猪NASH模型中DRD2拮抗剂阻断纤维化并恢复肝脏结构。
临床怎么用
- DRD2拮抗剂可能成为治疗NASH肝纤维化的潜在策略,但需进一步临床验证。
局限性
- 研究主要基于动物模型和体外筛选,人类临床数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Currently there is no effective treatment for liver fibrosis, which is one of the main histological determinants of non-alcoholic steatohepatitis (NASH). While Hippo/YAP (Yes-associated protein) signaling is essential for liver regeneration, its aberrant activation frequently leads to fibrosis and tumorigenesis. Unravelling "context-specific" contributions of YAP in liver repair might help selectively bypass fibrosis and preserve the pro-regenerative YAP function in hepatic diseases. METHODS: We used murine liver fibrosis and minipig NASH models, and liver biopsies from patients with cirrhosis. Single-cell RNA-sequencing (scRNA-Seq) was performed, and a G-protein-coupled receptor (GPCR) ligand screening system was used to identify cell-selective YAP inhibitors. RESULTS: YAP levels in macrophages are increased in the livers of humans and mice with liver fibrosis. The increase in type I interferon and attenuation of hepatic fibrosis observed in mice specifically lacking Yap1 in myeloid cells provided further evidence for the fibrogenic role of macrophage YAP. ScRNA-Seq further showed that defective YAP pathway signaling in macrophages diminished a fibrogenic vascular endothelial cell subset that exhibited profibrotic molecular signatures such as angiocrine CTGF and VCAM1 expression. To specifically target fibrogenic YAP in macrophages, we utilized a GPCR ligand screening system and identified a dopamine receptor D2 (DRD2) antagonist that selectively blocked YAP in macrophages but not hepatocytes. Genetic and pharmacological targeting of macrophage DRD2 attenuated liver fibrosis. In a large animal (minipig) NASH model recapitulating human pathology, the DRD2 antagonist blocked fibrosis and restored hepatic architecture. CONCLUSIONS: DRD2 antagonism selectively targets YAP-dependent fibrogenic crosstalk between macrophages and CTGF+VCAM1+ vascular niche, promoting liver regeneration over fibrosis in both rodent and large animal models. LAY SUMMARY: Fibrosis in the liver is one of the main histological determinants of non-alcoholic steatohepatitis (NASH), a disease paralleling a worldwide surge in metabolic syndromes. Our study demonstrates that a macrophage-specific deficiency in Yes-associated protein (YAP) attenuates liver fibrosis. Dopamine receptor D2 (DRD2) antagonism selectively blocks YAP in macrophages and thwarts liver fibrosis in both rodent and large animal models, and thus holds potential for the treatment of NASH.
引用
- Qing J, Ren Y, Zhang Y, et al. Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis. J Hepatol. 2021. PMID: 34648896. doi:10.1016/j.jhep.2021.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。